ライフサイエンスコーパス: baclofen

1 ying clinical effect of inrathecally infused baclofen.

2 ve agonist THIP (10 mum) were potentiated by baclofen.

3 neurons, as did the GABA(B) receptor agonist baclofen.

4 ffective when the training was combined with baclofen.

5 idative phosphorylation, and withdrawal from baclofen.

6 cantly blocked feeding elicited by NAC shell baclofen.

7 +) channel blocker facilitated the effect of baclofen.

8 transmission, studied with the GABAB agonist baclofen.

9 the application of diazepam or low doses of baclofen.

10 pecified dementia within 30 days of starting baclofen.

11 but not PV-IPSCs to a GABAb receptor agonist baclofen.

12 from that of the GABA(B)R agonists GABA and baclofen.

13 d GABAergic inhibition with this low dose of baclofen.

14 g after SCI and restored by long-term use of baclofen.

15 f magnitude greater than the pharmaceutical, baclofen.

16 he gamma aminobutyric acid (GABA(B)) agonist baclofen (0-ng, 25-ng, or 50-ng total infusion; Experime

17 ion training (experiment 1) or muscimol plus baclofen (0.1 and 1.0 mM) or vehicle infusions into the

18 ministration of the GABA(B) receptor agonist baclofen (0.1-10 microg/50 microL) on evoked responses o

19 A by GABAA+GABAB receptor agonists (muscimol+baclofen, 0.03+0.3 nmol) on cue-induced methamphetamine

20 e hyperpolarized by both the GABA(B) agonist baclofen (1 microM) and the kappa-opioid receptor agonis

21 Systemic administration of R-(+)-baclofen (1.25 mg/kg, i.p.) did not alter total distance

22 ort-term synaptic depression appeared during baclofen (10 mum) application when initial Pr was greate

23 ation of presynaptic GABAB receptors by (+/-)baclofen (10 mum), GABA (2 mm) or by GABA uptake inhibit

24 ts, GABA (2 mm), muscimol (10-100 microM) or baclofen (10-100 microM), in the presence of TTX, each o

25 Rats were subsequently administered baclofen (2 mg/kg i.p. or vehicle) immediately after eac

26 In a separate experiment, systemic baclofen (2.5 mg/kg) decreased the amphetamine-induced i

27 u hybridization histochemistry revealed that baclofen (2.5 mg/kg, i.p.) decreased the ability of amph

28 Baclofen (20 microM), an agonist for the G-protein-coupl

29 The GABA(B) receptor agonist baclofen (20 mum) enhanced GABA(A) currents.

30 Muscimol (25 ng) and baclofen (200 microg) each significantly and equi-effect

31 intakes were assessed following vehicle and baclofen (200 ng) in each site.

32 sessed for food intake following vehicle and baclofen (200 ng) in each site.

33 (diazepam, 6 of 6 patients treated, and oral baclofen, 3 of 3 treated) and immunotherapy (intravenous

34 l inactivation of the OFC with muscimol plus baclofen (50 + 50 ng/side) decreased relapse to fentanyl

35 methanesulfonate (U-50,488H; 1 microM), and baclofen (50 microM) inhibited Ca2+ currents, whereas th

36 her GABA(A) and GABA(B) agonists (muscimol + baclofen, 50 + 50 ng/side), Drd1-Drd2 antagonist (flupen

37 dent participants were randomized to receive baclofen (60 mg/d; 20 mg t.i.d.) or placebo.

38 In Experiment 2, we tested the influence of baclofen (a GABABR agonist) and diazepam (a classical be

39 Administration of baclofen, a GABA(B) agonist known to attenuate piriform

40 Baclofen, a gamma-aminobutyric acid receptor(B) agonist,

41 observed following chronic treatment with R-baclofen, a selective agonist of GABAB receptors.

42 f GHB, and the effect of GHB was mimicked by baclofen, a selective GABAB receptor agonist, whereas th

43 Application of baclofen, a specific GABA(B) receptor agonist, inhibited

44 e in relapse prevention, we examined whether baclofen-a GABAB receptor agonist that reduces mesolimbi

45 In the absence of TTX, baclofen activated an outward K+ current that hyperpolar

46 A GABA(B)R agonist, baclofen, activated Akt and stimulated neutrophil-direct

47 ocaine exposure both synaptically evoked and baclofen-activated GABA(B)R-GIRK currents were significa

48 Thus, baclofen administered in conjunction with extinction tra

49 Baclofen administration in the VTA and NAC shell was pre

50 Baclofen administration in the VTA or NACs was also prec

51 to investigate the effects of chronic oral R-baclofen administration in two independently generated m

52 ither GABAA (e.g., muscimol) or GABAB (e.g., baclofen) agonists into either the shell region of the n

53 Baclofen also blocked the amphetamine-induced rise in SG

54 The GABAB receptor agonist baclofen also inhibited inward currents induced by CIM02

55 RGS6(-/-) mice administered baclofen also showed exaggerated motor coordination defi

56 Baclofen alters this history dependence by causing no in

57 tin, and a compounded topical gel containing baclofen, amitriptyline HCL, and ketamine, these agents

58 ol mice, whereas there was no difference for baclofen, an agonist at GABA(B) receptors.

59 f these reactions to the formal syntheses of baclofen and (+)-monomorine was demonstrated.

60 at 3 months was 38.9 (13.2) for intrathecal baclofen and 21.0 (4.6) for placebo (regression coeffici

61 aclofen treatment by either coapplication of baclofen and adenosine, or intracellular infusion of the

62 y examined the effect of the GABA(B) agonist baclofen and alpha-conotoxins Vc1.1 and RgIA on calcium

63 However, baclofen and CP55940 did not act identically, because on

64 odulation interventions, such as intrathecal baclofen and deep brain stimulation, are promising optio

65 ysed units from subjects who were not taking baclofen and fastest for units from the uninjured.

66 s from spinal cord injured subjects who take baclofen and have done so for a median of 7 years, 25 pa

67 Baclofen and morphine also dose-dependently ameliorated

68 nd that inhibition of LSr neurons with local baclofen and muscimol microinjection (0.3/0.03 nmol) blo

69 In contrast, combined subthreshold doses of baclofen and muscimol produced a significant synergistic

70 In the resting condition, a dose of baclofen and muscimol that blocked a behaviorally induce

71 on of the dlCPu with GABA receptor agonists (baclofen and muscimol) immediately prior to reinstatemen

72 ation, through infusion of the GABA agonists baclofen and muscimol, on place acquisition and reversal

73 Baclofen and somatostatin, agonists of Gi-coupled recept

74 The GABAB antagonist baclofen and the metabotropic glutamate receptor antagon

75 4-chlorobenzenepropanoic acid hydrochloride (baclofen) and GABA are increased at the constitutively a

76 that directly modulates GABAergic signaling (baclofen) and one agent that indirectly modifies NMDAR-m

77 toxin A), intrathecally administered drugs (baclofen), and surgery (neurectomy, rhizotomy) has becom

78 neurotransmitter release by neuropeptide Y, baclofen, and adenosine as revealed by [Zn]t closely res

79 Systemic muscimol or baclofen are antipruritic against both histamine-depende

80 Ondansetron, naltrexone, topiramate, and baclofen are examples.

81 terneuronal circuits, which are sensitive to baclofen, are part of the subcortical premotoneuronal ne

82 nsitivity of Abeta-fibre-evoked responses to baclofen, as well as an increased sensitivity of post-di

83 e range, 71-82]; 9707 [61%] patients started baclofen at >=20 mg/d and 6235 [39%] at <20 mg/d).

84 Application of baclofen at a high dose (10 mg/kg i.p.) reduced the powe

85 red in 108/9707 (1.11%) patients who started baclofen at greater than or equal to 20 mg per day and i

86 g per day and in 26/6235 (0.42%) who started baclofen at less than 20 mg per day; weighted RR, 3.54 (

87 Baclofen (at doses from 10(-9) to 10(-3) M) failed to di

88 ied agonists (NMDA, clonidine, muscimol, and baclofen) at several types of receptors [NMDA, alpha2-ad

89 e vSub with GABA receptor agonists (muscimol+baclofen) before the context-induced relapse tests and p

90 Finally, baclofen blocked the frequency-dependent depression of E

91 , pretreatment with GABA(B) receptor agonist baclofen blocked the rewarding effects of morphine as me

92 oncentration of the GABA(B) receptor agonist baclofen blocks ethanol but not flunitrazepam or pentoba

93 Also, GABA and the GABA(B) agonist baclofen both elicited increases of the inwardly rectify

94 nist (SB242084) or a GABAB receptor agonist (baclofen), but not a GABAA receptor channel blocker (pen

95 ent response to the GABA(B) receptor agonist baclofen, but not DAMGO.

96 e NAC shell, and reduced feeding elicited by baclofen, but not muscimol in the VTA.

97 y 5 years) use of the GABAb receptor agonist baclofen by SCI patients reduced MEP size during precisi

98 However, the GABA(B)R agonist baclofen can also promote excitability and seizure gener

99 Behaviourally, baclofen caused a significant reduction of visuomotor af

100 The selective GABA(B) agonist (R)-baclofen caused a similar response with an EC(50) of 7.1

101 the amplitude of granule-cell-evoked IPSCs, baclofen causes a change from paired-pulse depression to

102 s mitral cell glutamate release only weakly, baclofen causes a marked reduction in the amplitude of g

103 effects of ethanol, oxotremorine, nicotine, baclofen, clonidine, and the cannabinoid receptor agonis

104 At 5.0 mg/kg, baclofen completely blocked both total distance traveled

105 activity, because the GABAB receptor agonist baclofen continued to elicit these currents in the mutan

106 For example, inhibitors of vagal afferents-baclofen could be beneficial in patients.

107 t study extended this work by determining if baclofen could enhance the extinction of methamphetamine

108 possibility that GABA agonist drugs, such as baclofen, could impair these processes, potentially impa

109 nd lidocaine), nociceptive pain (ketoprofen, baclofen, cyclobenzaprine, and lidocaine), or mixed pain

110 ixed pain (ketamine, gabapentin, diclofenac, baclofen, cyclobenzaprine, and lidocaine), or placebo.

111 However, long-term (~6 years) use of baclofen decreased active long-interval intracortical in

112 triatum using the GABA agonists muscimol and baclofen decreased context-induced reinstatement.

113 Intra-VTA methylnaloxonium or baclofen decreased ethanol-induced CPP, whereas intra-NA

114 l inactivation of the Pir with muscimol plus baclofen decreased relapse to fentanyl seeking after vol

115 on-heightening effect of the GABA(B) agonist baclofen depended on the activation of 5-HT neurons in t

116 (R)-Baclofen depressed the amplitude of evoked excitatory po

117 At 2.5 mg/kg, baclofen did not alter spontaneous motor activity or tot

118 Overall baclofen did not alter transcranial magnetic stimulation

119 Baclofen disrupted retrieval behavior without affecting

120 The GABA(B)R agonist baclofen elicited an outward current in all neurons with

121 of mouse models of ASD, we tested both the R-baclofen enantiomer and the less potent S-baclofen enant

122 R-baclofen enantiomer and the less potent S-baclofen enantiomer in two inbred strains of mice that d

123 Baclofen enhanced the paired-pulse ratio and coefficient

124 , or a linked gene, influences SB242084- and baclofen-enhanced convulsions.

125 Baclofen evoked prominent barium-sensitive outward curre

126 ated with equivalent, dramatic reductions in baclofen-evoked current in CA1 neurons.

127 The impact of GIRK subunit ablation on baclofen-evoked current was consistent with observations

128 all of the barium-sensitive component of the baclofen-evoked current was eliminated with the ablation

129 icient dorsal root ganglia neurons had lower baclofen-evoked inhibition of high-voltage-activated cal

130 y-old pups given naloxone (Experiment 1A) or baclofen (Experiment 1B) before ethanol administration w

131 anol levels were not affected by naloxone or baclofen (Experiment 2).

132 The GABA(B) receptor agonist baclofen facilitates the extinction of morphine-induced

133 ngs converge with the prior demonstration of baclofen facilitating the extinction of morphine-induced

134 ore, but not shell, injections of muscimol + baclofen, flupenthixol, SCH39166, and raclopride reduced

135 have relatively specific treatments, such as baclofen for periodic alternating nystagmus, and reposit

136 to the bathing medium or mimicked by adding baclofen (GABA(B) receptor agonist; 100 microM) to norma

137 Systemic baclofen, gabapentin, tramadol, and morphine dose-depend

138 Prescription for oral baclofen greater than or equal to 20 mg per day vs less

139 available for 17 patients in the intrathecal baclofen group and 16 in the placebo group.

140 tency of agonists was: GABA = SKF97541 > (R)-Baclofen > 3-APPA.

141 Baclofen had no effect on water or sugar water intake wh

142 The GABAB agonist baclofen has been shown to alter ethanol intake in human

143 The orthosteric GABAB receptor agonist baclofen has been shown to suppress operant self-adminis

144 Here we show that baclofen has concentration-dependent effects on the hipp

145 Diphenhydramine, Ecstasy, and baclofen have recently been implicated as the etiology o

146 In the presence of tetrodotoxin (TTX), baclofen hyperpolarized (DeltaVmax = 5.6 mV, EC50 = 2.3

147 work is needed to investigate whether taking baclofen impacts motor rehabilitation in patients.

148 r a single 10 mg dose of the GABA(B) agonist baclofen impaired motor sequence learning and visuomotor

149 To evaluate R-baclofen in a broader range of mouse models of ASD, we t

150 The present study assessed the effects of baclofen in a variation on a new mouse model of binge-li

151 ing responses elicited by either muscimol or baclofen in either the VTA and NAC shell following pretr

152 These findings encourage investigations of R-baclofen in other preclinical model systems.

153 d sensitivity of post-discharge responses to baclofen in spinal nerve ligated rats.

154 educed feeding elicited by muscimol, but not baclofen in the NAC shell, and reduced feeding elicited

155 eved by presession injection of muscimol and baclofen) in a novel two-reward choice task.

156 Here, we examined the effect of 10 mg of baclofen, in 20 young healthy individuals, and found tha

157 g effects (opioid antagonists decreasing and baclofen increasing food intake).

158 ignificantly blocked feeding elicited by VTA baclofen, indicating a robust and bidirectional GABA-B/G

159 ed but did not block feeding elicited by VTA baclofen, indicating a unidirectional interaction GABA-B

160 he basolateral amygdala (BLA) and potentiate baclofen-induced currents.

161 Baclofen-induced feeding elicited from the NAC was signi

162 Baclofen-induced feeding elicited from the VTA was signi

163 in the VTA, and correspondingly, whether VTA baclofen-induced feeding was dose-dependently blocked by

164 uculline, into the VTA, and then whether VTA baclofen-induced feeding was dose-dependently blocked by

165 low NACs NBNI dose significantly reduced VTA baclofen-induced feeding, indicating a bidirectional kap

166 ondingly, NACs NTX significantly reduced VTA baclofen-induced feeding, indicating a robust and bidire

167 uced feeding, NACs BFNA failed to affect VTA baclofen-induced feeding, indicating a unidirectional mu

168 duced feeding, NACs NTI failed to affect VTA baclofen-induced feeding, indicating a weak unidirection

169 high, but not low VTA BFNA dose reduced NACs baclofen-induced feeding, NACs BFNA failed to affect VTA

170 hereas VTA NTI only transiently reduced NACs baclofen-induced feeding, NACs NTI failed to affect VTA

171 Whereas VTA NBNI at both doses reduced NACs baclofen-induced feeding, the high, but not low NACs NBN

172 VTA NTX significantly reduced NACs baclofen-induced feeding.

173 ficant delay in the deactivation kinetics of baclofen-induced GIRK channel currents.

174 tic mechanism because ephedrine also reduced baclofen-induced hyperpolarization by 28%.

175 -induced hyperpolarization and inhibition of baclofen-induced hyperpolarization were abolished when s

176 ne (1-10 microM) and SR95531 (10 microM) and baclofen-induced responses were sensitive to 2-hydroxy-s

177 found to be effective in vivo, potentiating baclofen-induced sedation/hypnosis in DBA mice when admi

178 young animals, the GABA(B) receptor agonist, baclofen, inhibited the amplitude of evoked EPSCs and IP

179 n of GABA(B) receptors further, we show that baclofen inhibits high-voltage-activated calcium current

180 Like VTA baclofen injection, injection of dopamine receptor antag

181 Muscimol+baclofen injections into CeA but not BLA decreased cue-i

182 Muscimol+baclofen injections into dmPFC, vmPFC, or OFC during lat

183 itionally, renewal was blocked by muscimol + baclofen injections into LH.

184 one hemisphere plus unilateral muscimol plus baclofen injections into the OFC in the contralateral, b

185 Unilateral muscimol plus baclofen injections into the Pir in one hemisphere plus

186 nursing behavior, and control injections of baclofen into the region dorsal to VTA were ineffective.

187 blocked by injection of the GABA(B) agonist baclofen into the VTA.

188 Injections of muscimol + baclofen into ventral mPFC in one hemisphere and D(1)-fa

189 Unilateral injections of muscimol + baclofen into ventral mPFC or SCH 23390 into the accumbe

190 lthough at a high concentration (10 microM), baclofen invariably resulted in hyperpolarization, at lo

191 Baclofen is a GABA(B) agonist prescribed as a treatment

192 Baclofen is a GABAB receptor agonist commonly used to re

193 Baclofen is a promising tool to explore whether medial p

194 this effect is that the apparent affinity of baclofen is strongly reduced during physiologically rele

195 The GABA(B) agonist baclofen is taken daily as a treatment for spasticity by

196 vels may require more extensive therapy when baclofen is used chronically.

197 uding midazolam, flurazepam, avermectin Ba1, baclofen, isoguvacine, and propofol, at 1 or 10 muM, pro

198 Unexpectedly, at a lower dose (1 mg/kg), baclofen markedly increased gamma activity accompanied b

199 Our findings suggest that R-baclofen may have clinical utility for some of the core

200 In contrast, baclofen may have depressed the activity of all VTA proj

201 These results suggest that baclofen may inhibit the earliest type of drug cue-induc

202 spinal cord injured subjects who do not take baclofen (median: 10 years) and 45 units from uninjured

203 ther feeding elicited by the GABA-B agonist, baclofen microinjected into the NACs was dose-dependentl

204 ther feeding elicited by the GABA-B agonist, baclofen, microinjected into the NAC shell was dose-depe

205 Conversely, CeA inhibition by muscimol/baclofen microinjections prevented acquisition of cocain

206 replicate the initial efficacy findings for baclofen, modafinil, tiagabine, and topiramate.

207 , placebo-controlled clinical trials, namely baclofen, modafinil, tiagabine, and topiramate.

208 oltage-gated Ca(2+) channels as a target for baclofen modulation.

209 vation of OFC neurons with the GABA agonists baclofen + muscimol decreased cue-induced heroin seeking

210 Furthermore, similar to U0126, baclofen+muscimol-induced (B+M; 106.8/5.7 ng/0.5 mul/hem

211 eceived microinjections of the GABA agonists baclofen/muscimol (1/0.1 mM) into unilateral PL and the

212 L) region of the medial prefrontal cortex by baclofen/muscimol (B/M) during testing attenuates renewa

213 est this hypothesis, GABA receptor agonists (baclofen/muscimol) were microinjected into the anterior

214 l dorsal striatum was infused with saline or baclofen/muscimol, to temporarily inactivate the region.

215 ing with reversible inactivation techniques (baclofen/muscimol: 1.0/.1 mmol/L, .3 muL/side).

216 the increased feeding elicited by NAC shell baclofen, NAC shell bicuculline reduced but did not bloc

217 Neither baclofen nor a cannabinoid receptor agonist, CP55940, af

218 Baclofen normalized baseline gamma power without corresp

219 nificantly blocked the inhibitory effects of baclofen on evoked neuronal responses in control rats.

220 However, the inhibitory effect of baclofen on GABAergic and glycinergic spontaneous IPSCs

221 The effects of VTA baclofen on maternal behavior are similar to the effects

222 e the effects of the selective GABAB agonist baclofen on SON and PVN magnocellular neurones and to de

223 The short-term benefits of baclofen on spasticity (e.g. management of muscle spasms

224 paradigm were used to examine the effects of baclofen on subliminal cocaine (vs neutral) cues.

225 We examined the effects of baclofen on the relationship between an fEPSP during the

226 The effects of baclofen on voluntary motor output are limited and not y

227 his may contribute to the limited effects of baclofen on voluntary motor output in subjects with moto

228 GABAA + GABAB receptor agonists (muscimol + baclofen) on this effect.

229 y analogous to known GABAB agonists, such as baclofen or 3-aminopropyl phosphinic acid, are presented

230 ition by either the GABA(B) receptor agonist baclofen or intracellular guanosine 5'-O-(3-thio)triphos

231 ization (2:2) for treatment with intrathecal baclofen or placebo for 3 months via an implanted microi

232 Baclofen or saline was microinjected into the anterior o

233 eflux with reflux-reducing medication (e.g., baclofen) or antireflux surgery or on dampening visceral

234 can be modulated by means of GABA B agonist (baclofen) or opioid antagonist (naloxone) treatments.

235 ricted to patients who were newly prescribed baclofen; participants in the secondary cohort were new

236 Baclofen pretreatment blocked the induction of Fos in op

237 Intraventricular baclofen pretreatment in rats subjected to a stroke mode

238 The selective GABAB receptor agonist R-baclofen previously reversed social deficits and reduced

239 The GABAB agonist baclofen produced a significantly greater reduction in d

240 S-baclofen produced minimal effects at the same doses.

241 Baclofen produced similar magnitudes of increased food i

242 Baclofen produced similar magnitudes of increased food i

243 e biologically active compounds, such as (R)-baclofen, (R)-rolipram, (S)-curcumene, (S)-dehydrocurcum

244 combinations of GABA-A (muscimol) or GABA-B (baclofen) receptor agonists 15 to 20 minutes prior to in

245 Baclofen reduced binge-like ethanol intake when microinj

246 P55940 did not act identically, because only baclofen reduced facilitation and affected bouton releas

247 Comparatively, baclofen reduced pattern separation between odor categor

248 However, baclofen reduced the frequency of KCl-induced mEPSCs; an

249 In addition, baclofen reduced the frequency of miniature IPSCs but no

250 Baclofen reduced the frequency of spontaneous inhibitory

251 We find that the selective GABA(B) agonist baclofen reduces mitral cell recurrent inhibition mediat

252 st cases tested, the effects of muscimol and baclofen remained similar when synaptic transmission was

253 ophysiology of FXS as the GABABR agonist (R)-baclofen rescued the imbalances between excitatory and i

254 gender difference in the effects of E(2) on baclofen responses, there was no gender difference in 5-

255 addition, activation of GABA(B) receptors by baclofen restored the galanin effect under low Ca (2+) c

256 compounds with a per se nonsedative dose of baclofen resulted in shorter onset and longer duration o

257 We also assessed the effect of muscimol+baclofen reversible inactivation of vmPFC, dmPFC, and OF

258 rease in mIPSC frequency, it failed to block baclofen's reduction of mIPSC frequency.

259 Together, these results demonstrate that baclofen selectively maintains use-dependent modulation

260 In all groups of rats, spinal baclofen significantly reduced Abeta-, Adelta- and C-fib

261 Naloxone and baclofen significantly reduced the stimulating effect of

262 In contrast, baclofen specifically increased the N100 amplitude.

263 Baclofen, stimulated neutrophil chemotaxis and tubulin r

264 , the expression of GABA(B(1)) subunits, and baclofen-stimulated [35S]GTPgammaS binding, a measure of

265 functional GABA(B) receptors, as measured by baclofen-stimulated [35S]GTPgammaS binding, in the spina

266 stent with GABA(B) receptor desensitization, baclofen-stimulated GTPgammaS binding was reduced, and t

267 al GABA(B) circuits may be less sensitive to baclofen than spinal GABAB circuits.

268 patients with CKD who were newly prescribed baclofen, the 30-day incidence of encephalopathy was inc

269 With paralysis and baclofen, the median motor unit tetanic forces were sign

270 y of the GABA(B) agonist and muscle relaxant baclofen, there have been substantial advancements in th

271 the potency of the GABA(B) receptor agonist baclofen to activate G protein-coupled inwardly rectifyi

272 ly the potency of the GABAB receptor agonist baclofen to activate G-protein-coupled, inwardly rectify

273 educed reflex facilitation in subjects using baclofen to control spastic behaviours.

274 case reports have linked the muscle relaxant baclofen to encephalopathy in patients with chronic kidn

275 sing the GABA(B) receptor (GABA(B)R) agonist baclofen to engage presynaptic inhibition and field EPSP

276 A) and GABA(B) receptor agonists (muscimol + baclofen) to show a causal role of the AI in context-ind

277 We observed that baclofen-treated participants displayed significantly le

278 Short-term (4-24 h) baclofen treatment also significantly desensitized the i

279 amplitude could be partially restored after baclofen treatment by either coapplication of baclofen a

280 Intrathecal baclofen treatment is superior to placebo in achieving t

281 Intrathecal baclofen treatment is used for the treatment of dystonia

282 ovide evidence for the effect of intrathecal baclofen treatment on individual goals in patients with

283 R-baclofen treatment reversed social approach deficits in

284 The aim of our study was to evaluate whether baclofen use and paralysis due to cervical spinal cord i

285 Greater motor unit weakness with long-term baclofen use and paralysis will make the whole muscle we

286 isuomotor learning and suggests that chronic baclofen use could negatively impact aspects of motor re

287 ity), but the long-term effects of sustained baclofen use on skeletal muscle properties are unclear.

288 with rest but there was no effect of SCI or baclofen use.

289 s should be balanced against the benefits of baclofen use.

290 arison with 284 263 nonusers, both groups of baclofen users had a higher risk of encephalopathy (<20

291 was to compare the risk of encephalopathy in baclofen users vs nonusers.

292 on of N-type calcium channels in response to baclofen, Vc1.1 and RgIA was significantly reduced in GA

293 In contrast to GABA and baclofen, Vc1.1 changes Cav2.2 channel kinetics by incre

294 g the GTP analog GDP-beta-s, indicating that baclofen was acting on postsynaptic GABA(B) receptors.

295 alcium, whereas the GABA(B) receptor agonist baclofen was ineffective, suggesting that chloride-media

296 The effects of (R)-baclofen were blocked by the GABA(B) antagonist CGP 5243

297 d by the GABA(B) receptor (GABA(B)R) agonist baclofen were diminished in a dose-dependent manner in m

298 o 24 years who were eligible for intrathecal baclofen were included.

299 GABA-B receptors, the effects of muscimol or baclofen were studied.

300 ), active medical treatment (omeprazole plus baclofen, with desipramine added depending on symptoms),

301 ignant syndrome, malignant hyperthermia, and baclofen withdrawal.